BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas

Show other versions (1)
Bibliographic Details
Main Authors: Nyman, H, Jerkeman, M, Karjalainen-Lindsberg, M, Banham, A, Enblad, G, Leppa, S
Format: Conference item
Published: 2008
Description
Summary:

Similar Items